The National electronic Library for Medicines in the European Union (EU) has published a review that summarizes the clinical trial data investigating the safety and effectiveness of Lucentis, Macugen, and Iluvien in the treatment of diabetic macular edema. Diabetic macular edema (DME) is a common manifestation of diabetic retinopathy and can...

Genentech announced today that one of two Phase III studies evaluating monthly Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness....

The European Commission has granted Novartis a new indication for Lucentis (ranibizumab) to treat patients with visual impairment due to diabetic macular edema (DME), a leading cause of blindness in the working-age population in most developed countries. Laser therapy, the current standard of care, has provided stabilization of vision in many...

Systematic review and meta-analysis of the treatment of diabetic macular edema (DME) with intravitreal Avastin (bevacizumab, IVB) finds that IVB is an effective short-term treatment for diabetic macular edema, and that its efficacy wanes after 6 weeks. Diabetic retinopathy is the result of microvascular retinal changes. Hyperglycemia-induced...

Intravitreal Avastin (bevacizumab, IVB) injection as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy (PDR) improves the anatomical and functional outcomes of surgery, according to a new study. Diabetic retinopathy is the result of microvascular retinal changes. Hyperglycemia-induced pericyte death and...

Pycnogenol (Horphag Research) can improve microcirculation, retinal edema and visual acuity in the early stages of diabetic retinopathy, according to a new study. Pycnogenol is a nutritional supplement extracted from the bark of the French maritime pine tree. It contains a combination of procyanidins, bioflavonoids and organic acids....

A new study reports short-term regression of neovascularization after intravitreal Avastin (bevacizumab) in patients with proliferative diabetic retinopathy (PDR). Eighty eyes from 76 patients with active neovascularization of the disc (NVD) or elsewhere (NVE) caused by PDR were divided into four groups and treated with a single intravitreal...